Do mRNA Vaccines Help Introduce Cancer Survival Benefit? Are There Any Risks?

According to a claim by the American Association for Cancer Research (AACR), mRNA vaccines for COVID-19 are associated with higher PD-L1 expression in tumors and improved overall survival in patients with non–small cell lung cancer as well as metastatic melanoma also receiving immune checkpoint therapy such as Merck’s Keytruda. Does this mean that COVID-19 mRNA vaccines sensitize tumors to immunotherapy, meaning the provision of  a survival benefit to patients with cancer?

According to an entry of AACR’s news site Cancer Discovery News, this association is very much a possible reports Yaakov Zinberg, a writer for AACR’s Cancer Discovery News. But TrialSite cautions that such news cannot be interpreted as correlative evidence without further validating research